Laboratory Medicine ›› 2018, Vol. 33 ›› Issue (1): 1-9.DOI: 10.3969/j.issn.1673-8640.2018.01.0001
• Orginal Article • Next Articles
Received:
2017-05-11
Published:
2018-01-31
CLC Number:
ZHANG Yan, Thomas Jackson. Clinical mass spectrometry:principles of mass spectrometry for clinical laboratories[J]. Laboratory Medicine, 2018, 33(1): 1-9.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2018.01.0001
名称 | 色谱法 | 待测物类别 | 待测物分子质量 | 优点 | 缺点 |
---|---|---|---|---|---|
EI | GC | 非极性,可挥发 | 低-中 | 质量谱重复性高 | 与LC不兼容 |
CI | GC | 非极性,可挥发 | 低-中 | GC兼容样品信息 | 与LC不兼容 |
ESI | LC,SFC,CE | 极性 | 中-高 | 与许多生物样品兼容 | 受限于电离抑制 |
APCI | LC,SFC,CE | 极性、极性较小 | 较低-中 | 较ESI稳定 | 不及ESI敏感 |
APPI | LC, SFC, CE | 含芳香基团 | 较低-中 | 高信噪比 | 只能用于含芳香基团物质的检测 |
名称 | 色谱法 | 待测物类别 | 待测物分子质量 | 优点 | 缺点 |
---|---|---|---|---|---|
EI | GC | 非极性,可挥发 | 低-中 | 质量谱重复性高 | 与LC不兼容 |
CI | GC | 非极性,可挥发 | 低-中 | GC兼容样品信息 | 与LC不兼容 |
ESI | LC,SFC,CE | 极性 | 中-高 | 与许多生物样品兼容 | 受限于电离抑制 |
APCI | LC,SFC,CE | 极性、极性较小 | 较低-中 | 较ESI稳定 | 不及ESI敏感 |
APPI | LC, SFC, CE | 含芳香基团 | 较低-中 | 高信噪比 | 只能用于含芳香基团物质的检测 |
样品制备技术 | 优点 | 缺点 | 样品适用性 |
---|---|---|---|
稀释后直接进样 | 简单、成本低廉、快速 | 清除不彻底、非选择性、样品需稀释 | 尿液 |
蛋白沉淀 | 简单、成本低廉、快速 | 极低选择性、无法消除基质干扰 | 血液、血浆、 血清 |
液-液萃取 | 具有分析物类别特异性、可放大浓度 | 难以实现自动化 | 尿液、血浆、 血清、唾液 |
固相萃取法去除 蛋白质及脂质 | 简单、快速(如实现自动化)、易于 开发、可放大浓度、清除彻底 | 极低选择性 | 血液、血浆、 血清 |
固相萃取 | 方法开发复杂、耗材成本最高 | 所有种类样品 | |
快速(如实现自动化)、回收率高、具 分析物类别特异性、可放大浓度 |
样品制备技术 | 优点 | 缺点 | 样品适用性 |
---|---|---|---|
稀释后直接进样 | 简单、成本低廉、快速 | 清除不彻底、非选择性、样品需稀释 | 尿液 |
蛋白沉淀 | 简单、成本低廉、快速 | 极低选择性、无法消除基质干扰 | 血液、血浆、 血清 |
液-液萃取 | 具有分析物类别特异性、可放大浓度 | 难以实现自动化 | 尿液、血浆、 血清、唾液 |
固相萃取法去除 蛋白质及脂质 | 简单、快速(如实现自动化)、易于 开发、可放大浓度、清除彻底 | 极低选择性 | 血液、血浆、 血清 |
固相萃取 | 方法开发复杂、耗材成本最高 | 所有种类样品 | |
快速(如实现自动化)、回收率高、具 分析物类别特异性、可放大浓度 |
[1] | YOST R A, ENKE C G.Triple quadrupole mass spectrometry for direct mixture analysis and structure elucidation[J]. Anal Chem, 1979,51(12):1251-1264. |
[2] | SHACKLETON C.Clinical steroid mass spectrometry: a 45-year history culminating in HPLC-MS/MS becoming an essential tool for patient diagnosis[J]. J Steroid Biochem Mol Biol,2010,121(3-5): 481-490. |
[3] | LEHOTAY D C, CLARKE J T.Organic acidurias and related abnormalities[J]. Crit Rev Clin Lab Sci, 1995,32(4): 377-429. |
[4] | MILLINGTON D S, KODO N, NORWOOD D L, et al.Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism[J]. J Inherit Metab Dis, 1990,13(3): 321-324. |
[5] | BLAKLEY C R, VESTAL M L.Thermospray interface for liquid chromatography/mass spectrometry[J]. Anal Chem, 1983,55(4): 750-754. |
[6] | ADAWAY J E, KEEVIL B G, OWEN L J.Liquid chromatography tandem mass spectrometry in the clinical laboratory[J]. Ann Clin Biochem, 2015,52(Pt 1): 18-38. |
[7] | COTTER R J, SWATKOSKI S, BECKER L, et al.Time-of-flights and traps: from the Histone Code to Mars[J]. Eur J Mass Spectrom(Chichester), 2010, 16(3): 331-340. |
[8] | PLASS W R, DICKEL T, SCHEIDENBERGER C.Multiple-reflection time-of-flight mass spectrometry[J]. Int J Mass Spectrom,2013, 349-350 : 134-144. |
[9] | COMISAROW M B, MARSHALL A G.Frequency-sweep Fourier transform ion cyclotron resonance spectroscopy[J]. Chem Phys Lett, 1974,26(4): 489-490. |
[10] | COMISAROW M B, MARSHALL A G.Fourier transform ion cyclotron resonance spectroscopy[J]. Chem Phys Lett, 1974,25(2): 282-283. |
[11] | MAKAROV A.Electrostatic axially harmonic orbital trapping: a high-performance technique of mass analysis[J]. Anal Chem, 2000,72(6): 1156-1162. |
[12] | DE HOFFMANN E.Tandem mass spectrometry: a primer[J]. J Mass Spectrom, 1996,31(2): 129-137. |
[13] | KEBARLE P, VERKERK U H.A brief overview of the mechanisms involved in electrospray mass spectrometry[M].Weinheim:Wiley-VCH Verlag GmbH and Co. KGaA, 2010:1-35. |
[14] | GOHLKE R S.Time-of-flight mass spectrometry and gas-liquid partition chromatography[J]. Anal Chem, 1959,31: 535-541. |
[15] | GOHLKE R S, MCLAFFERTY F W.Early gas chromatography/mass spectrometry[J]. J Am Soc Mass Spectrom, 1993,4(5): 367-371. |
[16] | WILKINS C L, LAY J O.Identification of microorganisms by mass spectrometry[J]. Chem Anal, 2006,2006:169. |
[17] | TAKÁTS Z, WISEMAN J M, GOLOGAN B, et al. Mass spectrometry sampling under ambient conditions with desorption electrospray ionization[J]. Science, 2004,306(5695): 471-473. |
[18] | WAGNER M, TONOLI D, VARESIO E, et al.The use of mass spectrometry to analyze dried blood spots[J]. Mass Spectrom Rev, 2016,35(3): 361-438. |
[19] | RODUSHKIN I, ENGSTRÖM E, BAXTER D C. Isotopic analyses by ICP-MS in clinical samples[J]. Anal Bioanal Chem, 2013,405(9): 2785-2797. |
[20] | DELAFIORI J, RING G, FUREY A.Clinical applications of HPLC-ICP-MS element speciation: a review[J]. Talanta, 2016,153: 306-331. |
[21] | LUNDANES E, REUBSAET L, GREIBROKK T.Chromatography: basic principles, sample preparations and relate. Methods [M]. New Jersey:John Wiley and Sons,2013. |
[22] | HSIEH Y.Supercritical fluid chromatography-mass spectrometry[J]. Boca Raton:CRC Press,2010:277-296. |
[23] | PONTILLO C, FILIP S, BORRAS D M, et al.CE-MS-based proteomics in biomarker discovery and clinical application[J]. Proteomics Clin Appl, 2015,9(3-4): 322-334. |
[24] | GELL D A, GRANT R P, MACKAY J P.The detection and quantitation of protein oligomerization[J]. Adv Exp Med Biol, 2012,747: 19-41. |
[25] | LINGE K L, JARVIS K E.Quadrupole ICP-MS: introduction to instrumentation, measurement techniques and analytical capabilities[J]. Geostand Geoanal Res, 2009,33(4): 445-467. |
[26] | MEYER G M, MAURER H H, MEYER M R.Multiple stage MS in analysis of plasma, serum, urine and in vitro samples relevant to clinical and forensic toxicology[J]. Bioanalysis, 2016,8(5): 457-481. |
[27] | MESMIN C, VAN OOSTRUM J, DOMON B.Complexity reduction of clinical samples for routine mass spectrometric analysis[J]. Proteomics Clin Appl, 2016,10(4): 315-322. |
[28] | PERSONA K, MADEJ K, KNIHNICKI P, et al.Analytical methodologies for the determination of benzodiazepines in biological samples[J]. J Pharm Biomed Anal, 2015,113: 239-264. |
[29] | BOURGOGNE E, WAGNER M.Sample preparation and bioanalysis in mass spectrometry[J]. Ann Biol Clin(Paris), 2015,73(1): 11-23. |
[30] | FARHADI K, HATAMI M, MATIN A A.Microextraction techniques in therapeutic drug monitoring[J]. Biomed Chromatogr, 2012,26(8): 972-989. |
[31] | DEVENTER K, POZO O J, VERSTRAETE A G, et al.Dilute-and-shoot-liquid chromatography-mass spectrometry for urine analysis in doping control and analytical toxicology[J]. TrAC Trends Anal Chem, 2014,55: 1-13. |
[32] | FRITZ J S.Solid-phase extraction: principles, techniques and applications[J]. J Am Chem Society, 2000,122(49): 12411-12412. |
[33] | KUELPMANN W R, HANNAK D.Methods for clinical toxicological analysis[M]. Weinheim:Wiley-VCH Verlag GmbH and Co. KGaA, 2009:25-58. |
[34] | WUDY S A, HOMOKI J.Profiling steroids by gas chromatography-mass spectrometry: clinical applications[M]. Switzerland: S Karger AG, 2003:427-449. |
[35] | BAKER T C, HAN J, BORCHERS C H.Recent advancements in matrix-assisted laser desorption/ionization mass spectrometry imaging[J]. Curr Opin Biotechnol, 2017,43: 62-69. |
[36] | MARCINKOWSKA M, BARALKIEWICZ D.Multielemental speciation analysis by advanced hyphenated technique-HPLC/ICP-MS: a review[J]. Talanta, 2016,161: 177-204. |
[37] | THOMPSON B M, SCOTT B I, BOIANI J A.Understanding the Food and Drug Administration's jurisdiction over laboratory-developed tests and divisions between food, drug, and cosmetic act-regulated and Clinical Laboratory Improvement Amendments of 1988-regulated activities[J]. Clin Lab Med, 2016,36(3): 575-585. |
[38] | LEHMANN W D.A timeline of stable isotopes and mass spectrometry in the life sciences[J]. Mass Spectrom Rev, 2017,36(1): 58-85. |
[39] | ANNESLEY T M.Ion suppression in mass spectrometry[J]. Clin Chem, 2003,49(7): 1041-1044. |
[40] | VILJANTO M, SCARTH J, HINCKS P, et al.Application of testosterone to epitestosterone ratio to horse urine-a complementary approach to detect the administrations of testosterone and its pro-drugs in thoroughbred geldings[J]. Drug Test Anal, 2017,9(9): 1328-1336. |
[41] | CARTER G D, JONES J C, SHANNON J, et al.25-Hydroxyvitamin Dassays: potential interference from other circulating vitamin dmetabolites[J]. J Steroid Biochem Mol Biol, 2016,164: 134-138. |
[42] | ZHANG Y V, ROCKWOOD A.Impact of automation on mass spectrometry[J]. Clin Chim Acta, 2015,450: 298-303. |
[43] | FRENCH D, TERRAZAS E.The successful implementation of a licensed data management interface between a Sunquest(®) laboratory information system and an AB SCIEXTM mass spectrometer[J]. J Pathol Inform, 2013,4: 1. |
[44] | CORTELYOU-WARD K, RAMIREZ B, ROTARIUS T.The laboratory workforce shortage: a managerial perspective[J]. Health Care Manag (Frederick), 2011,30(2): 148-155. |
[45] | GARG U, ZHANG Y V.Mass spectrometry in clinical laboratory: applications in biomolecular analysis[J]. Methods Mol Biol, 2016,1378: 1-9. |
[46] | STOLL D R, CARR P W.Two-dimensional liquid chromatography: a state of the art tutorial[J]. Analytical Chem, 2017,89(1): 519-531. |
[47] | WEI D, LI M, KING K W, et al.Online and automated sample extraction[J]. Bioanalysis, 2015,7(17): 2227-2233. |
[48] | JOHNSON-DAVIS K L, JUENKE J M, THOMAS R L, et al. Everolimus method comparison between Waters MassTrakTM Immunosuppressants XE (IUO) kit and an in-house laboratory developed LC-MS/MS method in renal transplant patients[J]. Ann Clin Lab Sci, 2015,45(1): 27-31. |
[49] | SAITMAN A, METUSHI I G, MASON D S, et al.Evaluation of the Waters MassTrak LC-MS/MS assay for tacrolimus and a comparison to the Abbott architect immunoassay[J]. Ther Drug Monitor, 2016,38(3): 300-304. |
[50] | FERREIRA C R, YANNELL K E, JARMUSCH A K, et al.Ambient ionization mass spectrometry for point-of-care diagnostics and other clinical measurements[J]. Clin Chem, 2016,62(1): 99-110. |
[1] | MENG Xi, WEI Zhen, BAI Jianhua, HAO Xiaoke, ZENG Xianfei. Application of EWMA,HIQC and autoverification in primary medical institutions [J]. Laboratory Medicine, 2023, 38(9): 884-889. |
[2] | TAN Chunyan, ZHOU Ying, MO Zhijiang. Errors in Appendix B examples of WS/T 505—2017 and correction [J]. Laboratory Medicine, 2023, 38(6): 569-573. |
[3] | LI Xijiu, ZHOU Jianwei, ZHANG Qin, LONG Yunlin, WU Yingsong. Establishment and performance evaluation of UPLC-MS/MS for 6 markers in dried blood spots [J]. Laboratory Medicine, 2023, 38(5): 446-453. |
[4] | XU Weixin, CHEN Qing, DU Wenyong, GAO Yan. Plasma metabolic markers in patients with insomnia disorder [J]. Laboratory Medicine, 2023, 38(5): 454-459. |
[5] | WU Jie, LI Zenghe, CHEN Baorong, KONG Xujing. Establishment of traceable steroid hormone standard curve for dried blood spot samples [J]. Laboratory Medicine, 2023, 38(5): 489-493. |
[6] | Expert Group on the Consensus on Androgen Testing in Polycystic Ovary Syndrome China Association for Promotion of Health Science and Technology-Fertility Protection and Preservation Committee. Consensus on androgen testing in polycystic ovary syndrome [J]. Laboratory Medicine, 2023, 38(3): 203-208. |
[7] | YANG Xiaodong, LI Quanle, PAN Qingqing, ZHOU Jing, XIE Yangmin, ZOU Jihua, SHEN Min, ZHANG Man. Establishment and performance evaluation of candidate reference measurement procedure for the determination of immunosuppressive drugs in human whole blood by ID-LC-MS/MS [J]. Laboratory Medicine, 2023, 38(3): 215-222. |
[8] | WANG Yajie, ZU Bailing, GAN Chenxin, WU Jiaoxiang, SHU Jie, HANG Chen, CHEN Minghui, LIN Fujun, HU Zhigang, HUANG Biao, SHENG Huiming. Identification of plasma differential peptids in PLA2R1-related membranous nephropathy patients [J]. Laboratory Medicine, 2023, 38(3): 223-229. |
[9] | HUANG Yuan, CHEN Feng, MAO Leili, ZHANG Linglin, LÜ Qian, YAN Jun, CUI Wei. Application of serum peptidomics based on MALDI-TOF MS in the differential diagnosis of benign and malignant pancreatic diseases [J]. Laboratory Medicine, 2023, 38(1): 1-7. |
[10] | TANG Ningbo, LIU Guancai, LIU Xiaoyu, YANG Fengfan, GONG Zhimei, SUN Keqi. Establishment and evaluation for the determination of serum digitoxin as a candidate reference method [J]. Laboratory Medicine, 2022, 37(5): 456-462. |
[11] | OU Tong, ZHANG Bing, ZHANG Xiuming. Re-understanding about the rational application of clinical laboratory determination technologies for COVID-19 diagnosis [J]. Laboratory Medicine, 2022, 37(4): 303-308. |
[12] | LU Youli, YANG Shuangshuang, ZHANG Meiwei, OU Meixian, DONG Chunxia, SHEN Weiwei, JIANG Fengli, LI Shuijun. Simultaneous determination of 5 steroid hormones in human serum by ultra-performance liquid chromatography-tandem mass spectrometry and establishment of reference intervals in healthy adults [J]. Laboratory Medicine, 2022, 37(2): 165-173. |
[13] | XU Runhao, ZOU Chen, CAO Yun, CHEN Feng, LIU Yijing, ZHANG Shulin, ZHANG Jie. Roles of serum amino acid determinations in the diagnosis of early non-small-cell lung cancer [J]. Laboratory Medicine, 2022, 37(12): 1157-1163. |
[14] | LIU Congcong, LI Jiaping, ZHOU Hongwei. Performance evaluation of 2 mass spectrometry systems in clinical microbial identification [J]. Laboratory Medicine, 2022, 37(11): 1084-1088. |
[15] | KAN Lijuan, ZHANG Lijun, ZHANG Xiuming. Interpretation and application of 15 quality control indicators in clinical laboratories [J]. Laboratory Medicine, 2022, 37(10): 907-914. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||